BLRX vs. OVID, CDT, IXHL, PRLD, XBIT, TSVT, ME, ZVRA, RENB, and IVA
Should you be buying BioLineRx stock or one of its competitors? The main competitors of BioLineRx include Ovid Therapeutics (OVID), Conduit Pharmaceuticals (CDT), Incannex Healthcare (IXHL), Prelude Therapeutics (PRLD), XBiotech (XBIT), 2seventy bio (TSVT), 23andMe (ME), Zevra Therapeutics (ZVRA), Renovaro (RENB), and Inventiva (IVA). These companies are all part of the "pharmaceutical preparations" industry.
Ovid Therapeutics (NASDAQ:OVID) and BioLineRx (NASDAQ:BLRX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, valuation, media sentiment, analyst recommendations, community ranking, institutional ownership, profitability and earnings.
In the previous week, BioLineRx had 2 more articles in the media than Ovid Therapeutics. MarketBeat recorded 3 mentions for BioLineRx and 1 mentions for Ovid Therapeutics. BioLineRx's average media sentiment score of 1.34 beat Ovid Therapeutics' score of 0.67 indicating that Ovid Therapeutics is being referred to more favorably in the media.
Ovid Therapeutics has a beta of 0.58, indicating that its stock price is 42% less volatile than the S&P 500. Comparatively, BioLineRx has a beta of 1.54, indicating that its stock price is 54% more volatile than the S&P 500.
BioLineRx has a net margin of 0.00% compared to BioLineRx's net margin of -10,691.14%. BioLineRx's return on equity of -53.62% beat Ovid Therapeutics' return on equity.
BioLineRx received 159 more outperform votes than Ovid Therapeutics when rated by MarketBeat users. Likewise, 73.26% of users gave BioLineRx an outperform vote while only 70.55% of users gave Ovid Therapeutics an outperform vote.
72.2% of Ovid Therapeutics shares are held by institutional investors. Comparatively, 1.6% of BioLineRx shares are held by institutional investors. 13.3% of Ovid Therapeutics shares are held by insiders. Comparatively, 1.1% of BioLineRx shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Ovid Therapeutics currently has a consensus target price of $8.08, suggesting a potential upside of 173.09%. BioLineRx has a consensus target price of $21.00, suggesting a potential upside of 3,093.43%. Given Ovid Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe BioLineRx is more favorable than Ovid Therapeutics.
Ovid Therapeutics has higher earnings, but lower revenue than BioLineRx. Ovid Therapeutics is trading at a lower price-to-earnings ratio than BioLineRx, indicating that it is currently the more affordable of the two stocks.
Summary
Ovid Therapeutics and BioLineRx tied by winning 9 of the 18 factors compared between the two stocks.
Get BioLineRx News Delivered to You Automatically
Sign up to receive the latest news and ratings for BLRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BLRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BioLineRx Competitors List
Related Companies and Tools
